| dc.creator |
Afsar, Barış |
|
| dc.creator |
Copur, Sidar |
|
| dc.creator |
Sag, Alan A |
|
| dc.creator |
Ortiz, Alberto |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
Afsar, Rengin Elsurer |
|
| dc.date |
2021-06-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:16:17Z |
|
| dc.date.available |
2021-12-03T11:16:17Z |
|
| dc.identifier |
226bb91c-cef1-4ba5-92a4-54edc4de40da |
|
| dc.identifier |
10.1017/s000711452000358x |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/226bb91c-cef1-4ba5-92a4-54edc4de40da/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/90407 |
|
| dc.description |
Energy restriction (ER) has anti-ageing effects and probably protects from a range of chronic diseases including cancer, diabetes and chronic kidney disease (CKD). Specifically, ER has a positive impact on experimental kidney ageing, CKD (diabetic nephropathy, polycystic kidney disease) and acute kidney injury (nephrotoxic, ischaemia-reperfusion injury) through such mechanisms as increased autophagy, mitochondrial biogenesis and DNA repair, and decreased inflammation and oxidative stress. Key molecules contributing to ER-mediated kidney protection include adenosine monophosphate-activated protein kinase, sirtuin-1 and PPAR-gamma coactivator 1 alpha. However, CKD is a complex condition, and ER may potentially worsen CKD complications such as protein-energy wasting, bone-mineral disorders and impaired wound healing. ER mimetics are drugs, such as metformin and Na-glucose co-transporter-2 which mimic the action of ER. This review aims to provide comprehensive data regarding the effect of ER on CKD progression and outcomes. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence. |
|
| dc.type |
info:eu-repo/semantics/article |
|